Expression Profile of Selected MicroRNAs in the Peripheral Blood of Multiple Sclerosis Patients: a Multivariate Statistical Analysis with ROC Curve to Find New Biomarkers for Fingolimod

• Published in: Journal of molecular neuroscience Vol. 68; no. 1; pp. 153 - 161
• Main Authors: Eftekharian, Mohammad Mahdi, Komaki, Alireza, Mazdeh, Mehrdokht, Arsang-Jang, Shahram, Taheri, Mohammad, Ghafouri-Fard, Soudeh
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.05.2019; Springer Nature B.V
• Subjects: Adult; Autoimmune diseases; Biomarkers; Biomarkers - blood; Biomedical and Life Sciences; Biomedicine; Blood; Case-Control Studies; Cell Biology; Central nervous system; Female; Fingolimod Hydrochloride - therapeutic use; Humans; Immunosuppressive Agents - therapeutic use; Male; MicroRNAs - blood; Middle Aged; miRNA; Multiple sclerosis; Multiple Sclerosis - blood; Multiple Sclerosis - drug therapy; Multivariate statistical analysis; Neurochemistry; Neurology; Neurosciences; Patients; Peripheral blood; Proteomics; ROC Curve; Statistical analysis; Subgroups; Transcription; Fingolimod; miRNA; Multiple sclerosis
• ISSN: 0895-8696; 1559-1166; 1559-1166
• DOI: 10.1007/s12031-019-01294-z

Multiple sclerosis (MS) as a chronic autoimmune disease of the central nervous system (CNS) has been associated with dysregulation of several genes including miRNAs. In the present study, we assessed transcript levels of seven miRNAs (miR-96-5p, miR-211-5p, miR-15a, miR-34a-5p, miR-204-5p, miR-501-5p, and miR-524-5p) in the peripheral blood of MS patients compared with healthy subjects in association with response to fingolimod treatment. Expression levels of miR-211-5p and miR-34a-5p were significantly decreased in MS patients compared with healthy subjects ( P values of 0.002 and 0.47). While subgroup analysis showed downregulation of miR-211-5p in both fingolimod responders and non-responders, miR-34a-5p expression was only decreased in responders. Moreover, miR-204-5p was downregulated in non-responder male patients compared with male controls. The current study underscores the role of miRNAs in determination of response to fingolimod in MS patients.